478 related articles for article (PubMed ID: 9092797)
1. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
[TBL] [Abstract][Full Text] [Related]
2. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
3. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
Tepper CG; Boucher DL; Ryan PE; Ma AH; Xia L; Lee LF; Pretlow TG; Kung HJ
Cancer Res; 2002 Nov; 62(22):6606-14. PubMed ID: 12438256
[TBL] [Abstract][Full Text] [Related]
6. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
8. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
[TBL] [Abstract][Full Text] [Related]
9. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
Zhou J; Liu B; Geng G; Wu JH
Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
[TBL] [Abstract][Full Text] [Related]
11. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
12. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Warriar N; Pagé N; Koutsilieris M; Govindan MV
Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
[TBL] [Abstract][Full Text] [Related]
14. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
Culig Z; Stober J; Gast A; Peterziel H; Hobisch A; Radmayr C; Hittmair A; Bartsch G; Cato AC; Klocker H
Cancer Detect Prev; 1996; 20(1):68-75. PubMed ID: 8907206
[TBL] [Abstract][Full Text] [Related]
15. 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.
Miyamoto H; Marwah P; Marwah A; Lardy H; Chang C
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4440-4. PubMed ID: 12672951
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells.
Masiello D; Chen SY; Xu Y; Verhoeven MC; Choi E; Hollenberg AN; Balk SP
Mol Endocrinol; 2004 Oct; 18(10):2388-401. PubMed ID: 15256534
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
18. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.
Steketee K; Timmerman L; Ziel-van der Made AC; Doesburg P; Brinkmann AO; Trapman J
Int J Cancer; 2002 Jul; 100(3):309-17. PubMed ID: 12115546
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide.
Wang C; Young WJ; Chang C
Endocrine; 2000 Feb; 12(1):69-76. PubMed ID: 10855693
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
